Ricevi le ultime notizie sulle azioni Leap Therapeutics con aggiornamenti su tendenze di mercato, dati finanziari e analisi di Benzinga. Rimani informato sulle performance di LPTX

Ultime notizie per

LEAP THERAPEUTICS INC

Leap Therapeutics

Leap Therapeutics Inc is a biopharmaceutical company developing novel biomarker-targeted antibody therapies designed to treat patients with cancer by inhibiting fundamental tumor-promoting pathways, targeting cancer-specific cell surface molecules, and harnessing the immune system to attack cancer cells. The company's key clinical-stage drug candidate is sirexatamab (DKN-01), which targets Dickkopf-related protein 1 (DKK1) and is being studied in a clinical trial in patients with colorectal cancer. In addition, it also has a preclinical program to develop a proprietary monoclonal antibody, called FL-501 which works by inhibiting the GDF-15 protein.

Leap Therapeutics Inc

Earnings

Press Releases

Leap Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results

News

Driving the Future of Healthcare HIT, OSRH, THTX, LPTX, CSDX, Innovations in Health Insurance, Virtual Care, Oncology, and Chronic Disease Treatment

Leap Therapeutics to Host Virtual KOL Event to Discuss Sirexatamab (DKN-01) in Second-line Patients with Advanced Microsatellite Stable Colorectal Cancer

Leap Therapeutics to Present Preclinical Data of FL-501, a Novel GDF-15 Neutralizing Antibody, at the AACR 2025 Annual Meeting

Purple Biotech Appoints Shai Lankry as Chief Financial Officer

Leap Therapeutics Reports First Quarter 2025 Financial Results

Leap Therapeutics Reports Updated Clinical Data from Sirexatamab Colorectal Cancer Study and Announces Exploration of Strategic Alternatives

Leap Therapeutics Reports Second Quarter 2025 Financial Results

Penny Stocks

Leap Therapeutics to Present Final Clinical Data from Part B of the DeFianCe Study at the ESMO Congress 2025

Leap Therapeutics Announces $58.88 Million Private Placement in Cash Commitments Led by Winklevoss Capital to Initiate a Digital Asset Treasury Strategy

CSDX

GMDA

LPTX

OSRH

PPBT

THTX

Adaptimmune Therapeutics plc - American Depositary Shares

Adaptimmune Therapeutics

Akari Therapeutics Plc - American Depositary Shares

Akari Therapeutics

AlphaTON Capital

Boundless Bio

CASI Pharmaceuticals, Inc. - Ordinary Shares

CASI Pharmaceuticals

CollPlant Biotechnologies Ltd. - Ordinary Shares

CollPlant Biotechnologies

Elutia

Enlivex Therapeutics Ltd. - Ordinary Shares

Enlivex Therapeutics

Fortress Biotech, Inc. - 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock

Fortress Biotech

IO Biotech

Klotho Neurosciences, Inc. - Common Stock

Klotho Neurosciences

Kezar Life Sciences

Lunai Bioworks

MetaVia

Mural Oncology

Neuphoria Therapeutics Inc. - Common Stock

Neuphoria Therapeutics

NeuroSense Therapeutics Ltd. - Ordinary Shares

NeuroSense Therapeutics

OnKure Therapeutics, Inc. - Class A Common Stock

OnKure Therapeutics

Pluri

ProMIS Neurosciences Inc. - Common Shares

ProMIS Neurosciences

Q32 Bio

Rein Therapeutics

Sonnet BioTherapeutics Holdings, Inc. - Common Stock

Comments

Leap Therapeutics Notizie sulle azioni

Notizie

Ultime notizie per

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO